Generic NovoLog Mix 70/30
There are no generic NovoLog Mix 70/30 (insulin aspart protamine/insulin aspart) products licensed for sale at this time. NovoLog Mix 70/30 is a "biologic" drug that is not allowed to be manufactured in generic form in the U.S. Even if generic NovoLog Mix 70/30 were allowed to be produced, the medication is currently under a patent that does not expire until June 2014.
NovoLog® Mix 70/30 (insulin aspart protamine/insulin aspart) is a prescription diabetes medication. It is approved to treat both type 1 and type 2 diabetes. NovoLog Mix 70/30 contains 70 percent insulin aspart protamine (an intermediate-acting insulin) and 30 percent insulin aspart (a rapid-acting insulin). It provides blood sugar control with just two injections per day.
NovoLog Mix 70/30 is made by Novo Nordisk, Inc. At this time, there are no generic versions of NovoLog Mix 70/30 (or any other insulins) available.
There are at least two major obstacles preventing generic NovoLog Mix 70/30 from becoming available. First, NovoLog Mix 70/30 is protected by several patents, the first of which expired in September 2013 (the next patent is set to expire in June 2014). These patents may prevent any generic NovoLog Mix 70/30 from being sold in the United States.
Second, NovoLog Mix 70/30 is considered a "biologic" medication and is under different rules and laws than most other medications. At this point, generic biologics, including generic NovoLog Mix 70/30, are not allowed to be manufactured in the United States. Currently, legislation is underway that may change the laws concerning generic biologics (including insulin), but it is not clear when (or even if) this may happen.